106 related articles for article (PubMed ID: 18296466)
1. Phosphodiesterase 5 inhibitors and cystic fibrosis: correcting chloride channel dysfunction.
Clarke LL
Am J Respir Crit Care Med; 2008 Mar; 177(5):469-70. PubMed ID: 18296466
[No Abstract] [Full Text] [Related]
2. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis.
Lubamba B; Lecourt H; Lebacq J; Lebecque P; De Jonge H; Wallemacq P; Leal T
Am J Respir Crit Care Med; 2008 Mar; 177(5):506-15. PubMed ID: 18006891
[TBL] [Abstract][Full Text] [Related]
3. Is vardenafil "noninferior" or superior to sildenafil in the management of erectile dysfunction? Revisiting the biochemical, physiological, and clinical evidence.
Traish A; Kim N
J Sex Med; 2008 Jul; 5(7):1762-8; discussion 1768-9. PubMed ID: 18221281
[No Abstract] [Full Text] [Related]
4. Correction of chloride transport and mislocalization of CFTR protein by vardenafil in the gastrointestinal tract of cystic fibrosis mice.
Dhooghe B; Noël S; Bouzin C; Behets-Wydemans G; Leal T
PLoS One; 2013; 8(10):e77314. PubMed ID: 24204804
[TBL] [Abstract][Full Text] [Related]
5. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil.
Choi MK; Song IS
J Pharm Pharmacol; 2012 Aug; 64(8):1074-83. PubMed ID: 22775210
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacodynamics and pharmacokinetics of vardenafil in patients with erectile dysfunction].
Jin J; Guo Y
Zhonghua Nan Ke Xue; 2004 Sep; 10(9):711-6. PubMed ID: 15497717
[TBL] [Abstract][Full Text] [Related]
7. Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice.
Lubamba B; Lebacq J; Reychler G; Marbaix E; Wallemacq P; Lebecque P; Leal T
Eur Respir J; 2011 Jan; 37(1):72-8. PubMed ID: 20562123
[TBL] [Abstract][Full Text] [Related]
8. Classical activation of macrophages and vardenafil.
Muimo R
Clin Sci (Lond); 2017 Jun; 131(11):1141-1145. PubMed ID: 28533270
[TBL] [Abstract][Full Text] [Related]
9. [Effective and safe use of Levitra (Vardenafil) for treatment of erectile dysfunction].
Mazo EB; Gamidov SI; Ovchinnikov RI
Urologiia; 2004; (3):58-66. PubMed ID: 15199819
[No Abstract] [Full Text] [Related]
10. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
Gupta M; Kovar A; Meibohm B
J Clin Pharmacol; 2005 Sep; 45(9):987-1003. PubMed ID: 16100293
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
12. Validation of an LC-ESI-MS/MS method for the quantitation of phosphodiesterase-5 inhibitors and their main metabolites in rat serum and brain tissue samples.
Unceta N; Echeazarra L; Montaña M; Sallés J; Gómez-Caballero A; Goicolea MA; Barrio RJ
J Pharm Biomed Anal; 2012 Nov; 70():529-33. PubMed ID: 22647499
[TBL] [Abstract][Full Text] [Related]
13. Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS--application to forensic and therapeutic drug monitoring cases.
Rust KY; Wilkens H; Kaiser R; Bregel D; Wilske J; Kraemer T
Ther Drug Monit; 2012 Dec; 34(6):729-35. PubMed ID: 23128911
[TBL] [Abstract][Full Text] [Related]
14. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
15. [Effects of food and alcohol on the pharmacokinetics of vardenafil].
He ZJ
Zhonghua Nan Ke Xue; 2005 Jun; 11(6):477-9. PubMed ID: 15999499
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
17. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report.
Agrawal A; Tutuian R; Hila A; Castell DO
Dig Dis Sci; 2005 Nov; 50(11):2059-62. PubMed ID: 16240215
[No Abstract] [Full Text] [Related]
18. Failure of PDE5 inhibitor use: a case of nonresponder? (CME).
Chung E
J Sex Med; 2010 Apr; 7(4 Pt 1):1321-3. PubMed ID: 20492423
[No Abstract] [Full Text] [Related]
19. [PDE5 inhibitors in treatment of benign prostatic syndrome].
Sandner P; Tinel H; Stelte-Ludwig B; Huetter J; Neuser D; Bischoff E; Ulbrich E
Urologe A; 2007 Sep; 46(9):1189-92. PubMed ID: 17609921
[No Abstract] [Full Text] [Related]
20. Postmortem distribution of sildenafil in histological material.
Van Hee P; Neels H; Lambert W; Coucke V; Dedoncker M
J Anal Toxicol; 2006; 30(6):403-4; author reply 404-5. PubMed ID: 16872574
[No Abstract] [Full Text] [Related]
[Next] [New Search]
